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Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens
and mount protective immunity. We previously demonstrated that intranasal administration of targeted
galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we
assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that
would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show
that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that medi-
ated by unmodiﬁed liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced
higher levels of pro-inﬂammatory cytokines than unmodiﬁed liposomes in vitro. C57BL/6 mice thrice
immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high
levels of OVA-speciﬁc IgG antibodies in their serum. Spleen cells from mice receiving galactosylated lip-
osomes were restimulated with OVA and showed signiﬁcantly augmented levels of IFN-c, IL-4, IL-5 and
IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted
in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indi-
cate that nasal administration of a galactosylated liposome vaccine mediates the development of an
effective immunity against tumors and might be useful for further clinical anti-tumoral applications.
 2014 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
The mucosal surfaces, such as the gastrointestinal and respira-
tory tracts, represent the main entry site for most infectious
agents. Thus, mucosal immunity provides the ﬁrst line of defense
against harmful microorganisms. The nasopharynx-associated
lymphoid tissue (NALT) contains specialized M-like cells, which
are structurally similar to those present in Peyer’s patches in the
gut [1]. The structural and functional role of M cells is thought to
lie primarily in antigen uptake and transportation to underlying
lymphocytes and antigen presenting cells (APCs) in the mucosaltissues [2]. Mucosal surfaces also contain specialized dendritic cells
(DCs). DCs play a critical role in recognizing environmental patho-
gens, as well as in initiating and regulating adaptive immune
responses [3]. Upon capture of antigen, DCs are rapidly activated
by a complex process, become mature and migrate into the sec-
ondary lymphoid organs, such as the lymph nodes or the spleen,
where they present the processed antigenic peptides in the context
of either MHC class I or II molecules to CD4 + or CD8 + T lympho-
cytes, thereby triggering adaptive immune responses [4,5]. In addi-
tion, mature DCs also release a variety of cytokines and
chemokines to regulate both the innate and adaptive immune
responses [6]. Thus, a number of studies have been aimed at devel-
oping effective mucosal vaccines to induce protective immunity
against cancer and viral infection [7]. Recently, next-generation
mucosal vaccines based on synthetic antigens, such as subunit pro-
tein, peptide and DNA, have shown potential for the development
of safe and effective vaccination strategies [8]. However, due to
their weak immunogenicity and low cellular uptake efﬁcacy by
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multiple or larger doses to reach a satisfactory level of immune
protection [9]. Thus, a more effective delivery system is required
to enhance the efﬁcacy of mucosal vaccines.
Liposomes are small particulate vesicles formed from phospho-
lipid bilayers that can be used to encapsulate antigen or immuno-
modulatory molecules. Past studies have reported that liposomes
are capable of improving the delivery of antigens across mucosal
membranes [10] and enhancing the immunogenicity of various
antigens to boost the cellular or humoral immune response
[11–13]. Our previous studies also demonstrated that intranasal
immunization of inactivated virus encapsulated in a liposome [14]
or co-administrated with immunostimulatory molecules [15] can
successfully promote efﬁcient mucosal and systemic antibody
responses. Recently, surface modiﬁcation of the targeting ligands
and antibodies, which are speciﬁcally recognized by receptors on
the surface of APCs, has shown the potential to improve the uptake
of liposomes and better induce effective immunity against viruses
or tumors [16,17].
C-type lectin receptors (CLRs) expressed by DCs are particularly
important for the recognition of glycosylated self-antigens or for-
eign pathogens. CLRs interact with these antigens mainly through
the recognition of carbohydrate structures, such asmannose, fucose
and glucan, and promote endocytosis, leading to the processing and
presentation of antigens on MHC class I and II molecules [18].
Macrophage galactose-type C-type lectins (MGL) in humans and
mice are type II transmembrane glycoproteins with the capacity
to bind to galactose, N-acetylgalactosamine and Lewis X as mono-
or oligosaccharides [19]. It has been shown that the terminal
galactose has a high afﬁnity for mouse MGL receptors on murine
macrophages [20]. Furthermore, previous studies have identiﬁed
MGL expression on immature DCs in humans and mice and have
shown that MGL mediates the uptake of antigens containing
GalNAc residues [21,22]. Thus, galactose is a potent candidate
ligand for targeting APCs to induce effective immunity.
We have recently demonstrated that incorporating galactose-
1,2-didodecanoyl-sn-glycero-3-phosphoethanolamine (DLPE) into
liposomal bilayers as targeted antigen delivery carriers (galactosy-
lated liposomes) resulted in an increase in the uptake and produc-
tion of cytokines by macrophages [23]. Mice given galactosylated
liposomes intranasally showed a signiﬁcant increase in mucosal
secretory immunoglobulin A (s-IgA) and serum IgG antibody
responses. DCs are widely accepted as an ideal platform for vaccine
design. However, there has been little discussion about the poten-
tial of galactosylated liposomes to target DCs. The aim of this study
was to evaluate and validate whether galactosylated liposomes
could act as an effective DC-targeted mucosal vaccine that could
induce systemic antitumor immunity as well as antibody
responses. Our results show that galactosylated liposomes effec-
tively facilitated antigen uptake by DCs both in vitro and in vivo.
In addition, we established the protective efﬁcacy of ovalbumin
(OVA)-encapsulated galactosylated liposomes as a mucosal vaccine
against tumor growth.2. Materials and methods
2.1. Materials
Phosphatidylcholine was purchased from Degussa, Hamburg,
Germany. Cholesterol, 1,10-dioctadecyl-3,3,30,30-tetramethylindo-
carbocyanine perchlorate (DiI), OVA, carbonate–bicarbonate and
organic solvents were purchased from Sigma–Aldrich (St. Louis,
MO, USA). The galactosyl lipids (alpha-galactosyl-DLPE or beta-
galactosyl-DLPE) were prepared by conjugation of galactose with
DLPE, as described previously [23]. Horseradish peroxidase(HRP)-conjugated goat anti-mouse IgG and IgA were purchased
from Bethyl Laboratories (TX, USA). Fetal bovine serum (FBS), pen-
icillin and streptomycin were purchased from Gibco. The mouse
cytokine kit interleukin (IL)-4, IL-5, IL-6 and interferon (IFN)-c,
ﬂuorochrome-labeled anti-mouse monoclonal antibodies CD11c,
CD80, CD86, major histocompatibility complex class II (MHC-II)
and BD Cytoﬁx/Cytoperm Plus (with GolgiPlug) were purchased
from BD Biosciences (CA, USA). 3,30,5,50-tetramethyl benzidine
(TMB) was purchased from Bionovas Biotechnology (Ann Arbor,
MI, USA). C57BL/6 female mice (6–8 weeks old) were obtained
from the BioLASCO Taiwan Co., Ltd. and acclimated for 1 week
prior to the study. All animal experiments were conducted in spe-
ciﬁc pathogen-free conditions and in compliance with guidelines
provided by the Taipei Medical University of Science and Technol-
ogy for the care and use of animals for research purposes. The
E.G7-OVA cell line was obtained from the Food Industry Research
and Development Institute (Hsinchu, Taiwan) and maintained in
complete RPMI 1640 medium containing 10% heat-inactivated
fetal bovine serum, penicillin (100 U ml–1) and streptomycin
(100 lml1) at 37 C in 5% CO2.2.2. Preparation and characterization of liposomes
Liposomes were prepared as described previously [23]. Brieﬂy,
thin ﬁlms were obtained through the rotary evaporation of
chloroform solutions with a 4:4:0.5 lipid molar ratio of phosphati-
dylcholine:cholesterol:galactosyl lipid (alpha-galactosyl-DLPE or
beta-galactosyl-DLPE) using a ﬁnal lipid concentration of 2 mM.
The lipid ﬁlms were maintained under vacuum for 60 min to
remove residual organic solvents. Phosphate-buffered saline (PBS)
containing 5 mg ml1 OVA was added to the dried lipid ﬁlm, and
multilamellar vesicles were prepared by intense vortex dispersion.
The vesicles were extruded 10 times through a 1 lm pore polycar-
bonate membrane to form galactosylated liposomes (alpha-gal-
liposome or beta-gal-liposome). The amount of entrapped OVA
was measured by Bio-Rad protein assay, and non-encapsulated
OVA was removed by centrifugation. The OVA-encapsulated
unmodiﬁed liposomes (bare-liposome) were also prepared accord-
ing to the above procedure. Equivalent quantities of galactose were
added to bare-liposome to form a galactose-mixed-liposome (gal-
mixed-liposome).
To evaluate the uptake of liposomes by dendritic cells, DiI-
labeled liposomes were also prepared by adding 0.04 mol% DiI
(percentage of total lipid moles) to chloroform solutions according
to the above procedure. Free DiI and DiI aggregates were removed
by centrifugation. The particle size and zeta potential of the result-
ing preparations (200 ll diluted in 4 ml of distilled deionized
water) were conﬁrmed by dynamic light scattering analysis using
a particle analyzer (BIC 90 Plus, Brookhaven Instruments, Holts-
ville, NY, USA).2.3. Generation of bone-marrow-derived dendritic cells (BMDCs)
Mouse BMDCswere generated according to a published protocol
[24]. In brief, bone marrow cells were isolated from C57BL/6 mouse
femurs and tibias and passed through a 100 lM cell strainer. The
red blood cells were lysed using BD Pharm Lyse lysis buffer. The
remaining cells were cultured in RPMI 1640 medium (containing
10% heat-inactivated FBS, 100 U ml1 penicillin and 100 lg ml1
streptomycin) supplemented with granulocyte macrophage
colony-stimulating factor (1000 U ml1) and IL-4 (500 U ml1) at
37 C in 5% CO2 for 6 days to acquire immature BMDCs. The per-
centage of CD11c+ cells was veriﬁed by ﬂow cytometry, and the
cells (ﬁnal percentage of CD11c+ cells was 85–90%) were used for
further in vitro experiments.
Table 1
Physicochemical characteristics of various liposomal formulations.
Formulation Particle
diameter (nm)
Polydispersity
index
OVA encapsulation
efﬁciency (%)
Bare-liposome 997.17 ± 15.05 0.233 ± 0.017 36.2 ± 2.7
Gal-mixed-liposome 1078.3 ± 35.6 0.236 ± 0.014 35.7 ± 2.1
Alpha-gal-liposome 988.63 ± 16.35 0.249 ± 0.009 38.6 ± 1.8
Beta-gal-liposome 991.8 ± 19.95 0.221 ± 0.012 40.8 ± 2.3
The liposomes used were multilamellar vesicles with a total lipid concentration of
2 mM. Results are expressed as the means ± SE of three independent experiments.
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Mouse BMDCs were seeded at a density of 106 cells per well in a
24-well plate and incubated with bare-liposomes, gal-mixed-lipo-
somes or galactosylated liposomes. After a 24 h incubation, cells
were labeled with phycoerythrin (PE) hamster anti-mouse CD80,
PE hamster anti-mouse CD86 and PE rat anti-mouse MHC-II mono-
clonal antibodies. The expression of CD80, CD86 and MHC-II on
BMDCs was measured by ﬂow cytometry (BD FACSCalibur System).
For the in vitro cellular uptake assay, mouse BMDCs were incu-
bated with various DiI-labeled liposome formulations for 6 and
18 h. Following the incubation, cells were harvested and washed
three times with PBS, then analyzed immediately using ﬂow
cytometry. The data are presented as the mean ﬂuorescent signal
for the 10,000 cells collected.
2.5. Cytokine proﬁle of stimulated cells
Mouse BMDCs were seeded at a density of 106 cells per well in a
24-well plate and incubated with various liposome formulations
(ﬁnal OVA amount of 20 lg) at 37 C under 5% CO2 at 95% humidity.
After 24 h, the supernatants were harvested and the concentrations
of IL-1b, IL-6 and IL-12 were measured using mouse IL-1b, IL-6 and
IL-12 OptEIA sets according to the manufacturer’s instructions.
2.6. Evaluation of uptake of galactosylated liposomes by dendritic cells
in NALT
Four mice were given DiI-labeled bare-liposomes, alpha-gal-lip-
osomes or beta-gal-liposomes. After 24 h, single cell suspensions
were isolated from the NALT according to the method described
previously [25]. The cells were washed twice with PBS and then
stained with allophycocyanin-labeled anti-CD11c antibody to
detect dendritic cells. Fluorescent signals from DiI in the CD11c+
cells were analyzed, and the uptake of galactosylated liposomes
by dendritic cells in the NALT was evaluated.
2.7. Immunization of mice and tumor inoculation
C57BL/6 mice were randomly divided into ﬁve groups (10 mice
in each group) and immunized intranasally with 20 lg of OVA
encapsulated in bare-liposomes, gal-mixed-liposomes, alpha-gal-
liposomes, beta-gal-liposomes or PBS (40 ll). This immunization
procedure was repeated three times at 1 week intervals. One week
after the last immunization, six mice in each group were chal-
lenged with a dorsal subcutaneous (s.c.) injection of 2  105
E.G7-OVA cells. Tumor size was calculated twice a week using
the following formula: tumor volume (mm3) = length  (width2)/2.
2.8. Determination of OVA-speciﬁc antibodies
Blood samples were collected 1 week after the ﬁnal vaccination.
Serum samples were isolated by centrifugation for 30 min at room
temperature. MaxiSorpTM 96-well enzyme-linked immunosorbent
assay (ELISA) plates (Nunc, Rochester, NY, USA) were coated with
OVA suspended in 0.05 M carbonate–bicarbonate buffer at pH 9.6
and held overnight at 4 C. After washing the plates three times
with Tris-NaCl containing 0.05% Tween 20 (pH 8.0), Tris-NaCl with
1% bovine serum albumin (pH 8.0) was added to block nonspeciﬁc
binding sites. Serum samples were 2-fold serially diluted and then
added to the plates. HRP-conjugated goat anti-mouse IgG was sub-
sequently added to the plates to detect the bound anti-mouse IgG.
HRP activity was assessed using TMB as the substrate. The reaction
was stopped by the addition of 2 M H2SO4. The optical density (OD)
was measured using a SPECTRA MAX reader (Versamax Microplate
Reader, Molecular Devices, Toronto, Canada) at 450 nm. The anti-body titer was deﬁned as the reciprocal of the highest dilution that
had an OD value that was two times higher than the mean OD of
control mice serum.
2.9. In vitro spleen cell responses and intracellular cytokine staining
One week after the third immunization, four mice from each
group were sacriﬁced and single-cell suspensions from the spleens
of individual mice were prepared for in vitro spleen cell stimula-
tion and intracellular cytokine staining. The spleen cells were
seeded at a density of 5  106 cells per well in triplicate in 24-well
plates and cultured in RPMI 1640 medium (containing 10% heat-
inactivated FBS, 100 U ml1 penicillin and 100 lg ml1 streptomy-
cin) in the presence of 100 lg ml1 OVA. After a 72 h incubation,
the supernatants were collected and kept at 80 C until they were
used for the cytokine assay. Levels of IFN-c, IL-4, IL-5 and IL-6 were
quantiﬁed using mouse IFN-c, IL-4, IL-5 and IL-6 OptEIA sets
according to the manufacturer’s instructions. Intracellular staining
was performed with BD Cytoﬁx/Cytoperm Plus according to the
manufacturer’s instructions. The spleen cells were seeded at a den-
sity of 5  106 cells ml1. Cells were incubated with 100 lg ml1
OVA for 72 h, and 1 ll ml1 GolgiPlug was added during the last
5 h. The cells were stained with PE rat anti-mouse CD8 antibody
and allophycocyanin rat anti-mouse IFN-c antibody for the mea-
surement of IFN-c producing CD8 + T cells.
2.10. Statistical analysis
Data are reported as mean ± SE. The signiﬁcance of the data was
evaluated using Student’s t test; a p-value < 0.05 was considered
signiﬁcant.
3. Results
3.1. Physicochemical characteristics of galactosylated liposomes
Liposomes were prepared by the thin-ﬁlm hydration method.
To determine the effectiveness of the galactosylated liposomes as
a DC-targeted mucosal vaccine, OVA, a well-established model
antigen, was encapsulated within each of the liposome formula-
tions and extruded through a membrane with 1 lm pores. As
shown in Table 1, the particle sizes are approximately 1000 nm
and OVA encapsulation efﬁciencies are approximately 35–40%.
No signiﬁcant difference was observed in the mean particle diam-
eter or encapsulation efﬁciency among the four formulations.
3.2. The effect of galactosylated liposomes on the cellular uptake and
maturation of dendritic cells in vitro
Delivery of antigens to DCs is thought to be a prerequisite for
eliciting an effective immune response. The aim of this study was
to evaluate whether galactosylated liposomes could act as an effec-
tive DC-targetedmucosal vaccine that could facilitate antigen deliv-
ery atmucosal sites and induce effective systemic immune response
Fig. 1. A scheme of the working hypothesis. Upon intranasal immunization of galactosylated liposomes, speciﬁc recognition of galactose molecules by CLRs (MGL) on the
surface of dendritic cells at mucosal sites facilitated cellular uptake of liposome and antigen delivery to dendritic cells, and hence induced effective systemic antitumor
immune responses.
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somes, we ﬁrst evaluated the cellular uptake of different liposome
formulations by mouse BMDCs in vitro. Fluorescence-activated cell
sorting (FACS) analysis allowed for assessment of cell-associated
ﬂuorescence andwas used to examine the interaction of DiI-labeled
liposomeswith BMDCs. The results in Fig. 2A–C show that the incor-
poration of beta-galactosyl-DLPE signiﬁcantly promoted the uptake
of liposome by BMDCs (59.8% and 72.3% of DiI-ﬂuorescent signals
were observed after 6 and 18 h incubationwith beta-gal-liposomes,
respectively). The uptake of liposomes by BMDCs was slightly
enhanced by the incorporation of alpha-galactosyl-DLPE (19.7% of
DiI-ﬂuorescent signals were observed after 18 h incubation with
alpha-gal-liposomes). However, no signiﬁcant difference was
observed between galactose-mixed-liposomes and bare-liposomes.
DC maturation is another key control point for vaccine-induced
immune responses. The maturation is characterized by the
increased expression of MHC-II molecules, as well as the co-stim-
ulatory molecules CD80 and CD86 on the surface of DCs. Therefore,
we next assessed the effect of different liposome formulations on
DC maturation. As shown in Fig. 2B–D, BMDCs treated with OVA-
encapsulated bare-liposomes and gal-mixed-liposomes showed
signiﬁcant increase in expression of CD86 and MHC II. Further-
more, BMDCs treated with OVA-encapsulated alpha-gal-liposomes
and beta-gal-liposomes signiﬁcantly up-regulated their expression
of CD80, CD86 and MHC II on the cell surface compared with bare-
liposomes and gal-mixed-liposomes. This result suggests that the
efﬁcient uptake of alpha-gal-liposome and beta-gal-liposome
could induce the maturation of DCs and induce subsequent
immune responses.
3.3. Production of cytokines by DCs stimulated with galactosylated
liposomes in vitro
To assess whether galactosylated liposomes induced the secre-
tion of pro-inﬂammatory cytokines, BMDCs were treated with var-
ious liposome formulations for 24 h, and the production of
cytokineswas determinedby ELISA. As shown in Fig. 3A andB, treat-
ment of cells with each liposome formulation resulted in the pro-
duction of higher levels of IL-1b and IL-6 in comparison with the
control group. Furthermore, treating cells with alpha-gal-liposomes
andbeta-gal-liposomes led to higher levels of IL-1b and IL-6 produc-
tion compared with bare-liposomes and gal-mixed-liposomes(p < 0.05). The production of IL-12 was also signiﬁcantly elevated
in cells treated with alpha-gal-liposomes and beta-gal-liposomes
(Fig. 3C). Overall, liposomes incorporated with alpha-galactosyl-
DLPE or beta-galactosyl-DLPE enhanced the secretion of pro-inﬂam-
matory cytokines and were capable of inducing more efﬁcient
immune responses.
3.4. Uptake of galactosylated liposomes by dendritic cells in the NALT
Because resident APCs in the NALT play a critical role in antigen
uptake and presentation, we next evaluated the uptake of lipo-
somes by dendritic cells in the NALT. Allophycocyanin-labeled
anti-CD11c antibodywas used to detect dendritic cells, and DiI ﬂuo-
rescence in CD11c+ cells was analyzed to evaluate the uptake of lip-
osomes by dendritic cells in the NALT. In Fig. 4, the results of ﬂow
cytometry showed that 6.16 ± 0.91% and 7.50 ± 0.23% of CD11c+
cells in the NALT obtained frommice receiving alpha-gal-liposomes
and beta-gal-liposomes, respectively, were positive for DiI, while
only 3.35 ± 0.85% of the cells from mice given bare-liposomes con-
tained DiI ﬂuorescence. These results indicated that antigens
encapsulated in alpha-gal-liposomes and beta-gal-liposomes are
more effectively delivered into nasal dendritic cells to elicit
immune responses.
3.5. Antibody titer analysis
To investigate whether galactosylated liposomes induced a sys-
temic OVA-speciﬁc antibody response, OVA, a well-established
model antigen, was encapsulated in various liposome formula-
tions, and mice were immunized thrice intranasally. Serum sam-
ples were collected after the ﬁnal administration, and anti-OVA
antibodies were measured. Mice that received OVA alone via the
intranasal route did not experience any improvement in their sys-
temic antibody response (data no shown). However, improved
OVA-speciﬁc IgG antibody responses were observed in the serum
frommice receiving each of the liposome formulations (Fig. 5). Fur-
thermore, the levels of OVA-speciﬁc IgG antibody in the serum of
alpha-gal-liposome and beta-gal-liposome receiving mice were
signiﬁcantly higher than those in samples from mice receiving
bare-liposomes and gal-mixed-liposomes, suggesting that effective
antigen delivery to dendritic cells in the NALT led to effective
humoral immune responses.
Fig. 2. The effect of galactosylated liposomes on the cellular uptake and maturation of BMDCs. BMDCs were cultured with various DiI-labeled liposome formulations for 6 and
18 h. The uptake of DiI-labeled liposome was measured using ﬂow cytometry. Flow cytometry histograms of DiI-ﬂuorescent signals in BMDCs for 6 and 18 h (A, B) and
percentage of DiI-ﬂuorescent signals (C). BMDCs were cultured with medium (control) or different liposome formulations for 24 h. The expression of CD80, CD86 and MHC II
was measured using ﬂow cytometry (D–F). ⁄Signiﬁcant difference (p < 0.05) compared with the control group; #signiﬁcant difference (p < 0.05) compared with the bare-
liposome group. Similar results were obtained in three separate experiments.
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CD8 + T cell analysis
To assess whether galactosylated liposomes skew the immune
response toward a Th1 or Th2 immune response, spleen cellsfrom mice were obtained 1 week after the ﬁnal immunization
and cultured with 100 lg ml1 OVA for 72 h. The quantity of
Th1 (IFN-c) and Th2 (IL-4, IL-5 and IL-6) cytokines in the culture
supernatants was determined by ELISA. The results showed that
IFN-c production was signiﬁcantly increased in spleen cells from
Fig. 3. The effect of galactosylated liposomes on the production of cytokines by BMDCs. BMDCs were treated with various liposome formulations for 24 h. The supernatants
were collected and the production of cytokines IL-1b, IL-6 and IL-12 were determined by ELISA. The results are expressed as the means ± SE of triplicate experiments.
⁄Signiﬁcant difference (p < 0.05) compared with the control group; #signiﬁcant difference (p < 0.05) compared with the bare-liposome group.
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more, the levels of IFN-c induced by alpha-gal-liposomes and
beta-gal-liposomes were signiﬁcant higher than those induced
by bare-liposomes and gal-mixed-liposomes. A slight increase
in IL-4 secretion was found in the alpha-gal-liposome and beta-
gal-liposome groups (Fig. 6B). However, we observed that spleen
cell from mice receiving galactosylated liposomes showed signif-
icant increase in production of IL-5 and IL-6 (Fig. 6C and D). These
results indicated that effective antigen delivery of galactosylated
liposomes resulted in higher secretions of Th1 and Th2 cytokine.
Next, we investigated the cellular immune response induced by
intranasal immunization with galactosylated liposomes. IFN-c
producing CD8 + T cells were analyzed by ﬂow cytometry after
in vitro stimulation of spleen cells with whole OVA. As shown
in Fig. 7, the number of IFN-c producing CD8 + T cells was
increased in mice immunized with alpha-gal-liposomes
(p = 0.082) and signiﬁcantly increased in beta-gal-liposomes
(p < 0.05) compared with control group. Furthermore, we found
the number of IFN-c producing CD8 + T cells in the beta-gal-lip-
osomes group was signiﬁcantly increase compared with the
bare-liposome group and the gal-mixed-liposome group. These
results demonstrate that intranasal administration of galactosy-
lated liposomes induced effective Th1 and Th2 humoral and
cellular immune responses.3.7. Protective effect of intranasal administration of galactosylated
liposomes against EG7 tumor challenge
To evaluate whether galactosylated liposomes could be used as
a DC-targeted mucosal vaccine for the induction of protective
immune response against EG7 tumor challenge, mice were immu-
nized intranasally with various liposome formulations three times
at 1 week intervals. One week after the ﬁnal immunization, mice
were subcutaneously injected with 2  105 E.G7-OVA cells in the
dorsal region, and tumor growth was evaluated in each mouse
for 5 weeks. As shown in Fig. 8, the tumor growth in mice immu-
nized with galactosylated liposomes was markedly reduced,
whereas mice immunized with bare-liposomes or mixed-lipo-
somes showed only partial inhibition of tumor growth. All mice
immunized with beta-gal-liposomes completely rejected the
E.G7-OVA tumor cells until 35 days after tumor inoculation. These
results indicate that the DC-targeting and immunostimulatory
effects of galactosylated liposomes could induce a systemic
immune response that protects mice against tumor challenge.
4. Discussion
Nasal-associated lymphoid tissue is found in the murine upper
respiratory tract and is considered equivalent to the Waldeyer’s
Fig. 4. Uptake of galactosylated liposomes by dendritic cells in the NALT. C57BL/6 mice were given DiI-labeled bare-liposomes, alpha-gal-liposomes or beta-gal-liposomes
intranasally. After 24 h, single cell suspensions were isolated from the NALT and analyzed by FACS to evaluate DiI-labeled liposomes in CD11c+ cells (DCs). The CD11c+ cells
were ﬁrst gated based on allophycocyanin ﬂuorescence (upper panel), and then uptake of liposomes in gated cells was analyzed based on DiI (PE) ﬂuorescence. (A) Uptake of
DiI-liposomes by dendritic cells in NALT. Similar results were obtained in four separate experiments. (B) The percentage of uptake of DiI-liposomes by dendritic cells was
scored and represented in a histogram with a bar as the mean ± SE of four independent experiments. ⁄Signiﬁcant difference (p < 0.05) compared with the bare-liposome
group.
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Fig. 5. Effect of galactosylated liposomes on the serum OVA-speciﬁc IgG antibody
response. C57BL/6 mice were given various liposome formulations. One week after
the ﬁnal administration, serum samples were collected and anti-OVA antibodies
were measured by ELISA. The antibody titer was deﬁned as the reciprocal of the
highest dilution that had an OD value that was two times higher than the mean OD
of control mice serum. The results are expressed as the means ± SE. ⁄Signiﬁcant
difference (p < 0.05) compared with the control group; #signiﬁcant difference
(p < 0.05) compared with the bare-liposome group.
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associated epithelium, which contains antigen-sampling M cells
[27] as well as large numbers of B cells, T cells and APCs, such as
dendritic cells and macrophages [28]. Thus, the NALT contains all
of the lymphoid cells that are required for the initiation and regu-
lation of antigen-speciﬁc immune responses and is believed to be
the ideal route for vaccination. However, because of its close prox-
imity to a large number of commensal and dietary antigens in the
environment, the mucosal immune system multifacetedly regu-
lates the balance between pathogen surveillance and tolerance.
Thus, mucosal vaccines require potent adjuvants, vectors or deliv-
ery platforms for inducing effective immune responses [29].
Liposomes have excellent immunostimulatory properties,
including the capacity for sustained release of antigen over a pro-
longed time and preferential internalization by APCs; thus, the
higher antigen delivery efﬁcacy might promote the maturation
and antigen presentation of APCs [30]. Antigen-encapsulated lipo-
some formulations have been extensively used to enhance the
effectiveness of mucosal vaccines in the oral and nasal delivery
of antigens [31]. Recently, directly targeting APCs has been consid-
ered as a novel strategy to improve the efﬁciency of vaccines [32].
APCs have been shown to display various pattern-recognition
receptors (PRRs), such as C-type lectin receptors (CLRs) and Toll-
like receptors, which are critical for recognizing pathogen-associ-
ated molecular patterns and inducing immune responses. Among
the PRRs, CLRs are particularly important for the recognition and
uptake of glycosylated antigens [33]. In addition, several studies
have shown that CLRs directly or indirectly trigger distinct signal-
ing pathways by inducing speciﬁc cytokine secretion proﬁles,
which then determine T cell polarization [34]. Their ability to
mediate cellular uptake by APCs and regulate the immune
response makes CLRs potentially useful for targeting APCs. MGLs
are type II transmembrane glycoproteins with the ability to bind
galactose, N-acetylgalactosamine and Lewis X as mono- or oligo-
saccharides [19]. Recent studies have reported that MGL is
expressed on immature DCs in humans and mice [21,22]. For this
reason, MGL was suggested to mediate the uptake of antigens
and initiate the immune response in immature DCs. In our previ-
ous study, we prepared galactosyl lipids by conjugating a galactosemolecule with DLPE. The galactosyl lipid was incorporated into the
lipid bilayer of liposomes to form galactosylated liposomes [23].
Our results demonstrated that galactosylated liposomes can effec-
tively target murine macrophages to enhance antigen uptake and
cytokine production by murine macrophages. A signiﬁcant
increase in mucosal s-IgA and serum IgG antibody responses was
also observed in mice receiving galactosylated liposomes intrana-
sally. These results demonstrated the effectiveness of galactosylat-
ed liposomes as targeting carriers in intranasal immunization. To
further expand the utility of galactosylated liposomes for targeting
antigen delivery and for immune stimulation, the aim of the pres-
ent study was to investigate the targeting effect of galactosylated
liposomes on DCs and to evaluate whether galactosylated lipo-
somes can act as a dendritic cell-targeted mucosal vaccine for
inducing protective anti-tumor immunity.
The particle size of each liposome formulation is approximately
1000 nm. Therefore, the inﬂuence of particle size can be excluded as
a confounding factor. To investigate the targeting effects of galac-
tosylated liposomes, BMDCs were treated with various liposome
formulations. After 6 and 18 h co-culture, galactosylated liposomes,
especially beta-gal-liposomes, signiﬁcantly facilitated the efﬁciency
of uptake by BMDCs (Fig. 2). However, no signiﬁcant difference was
observed between the gal-mixed-liposomes and bare-liposomes.
We next evaluated the uptake of galactosylated liposomes in vivo.
Mice were intranasally treated with various DiI-labeled liposomes.
Twenty-four hours after single-dose administration, similar results
(Fig. 4) were observed as in the in vitro assays. DCs in the NALT took
up galactosylated liposomes more effectively than liposomes with-
out galactose modiﬁcations, suggesting that the recognition of
galactose residues facilitated the galactosylated liposome uptake.
Upon encapsulation of galactosylated liposomes, antigen could eas-
ily be delivered to DCs in a short time or with a low dose. It has been
indicated that repeated low-dose antigen concentration exposure
on themucosa results in the induction of tolerance [35]. Thus, galac-
tosylated liposomes have the potential capability to induce more
efﬁcient immune responses than conventional liposomes.
There are two signals involved in the activation of T cells: (i) the
recognition of themajorMHC–peptide complex by the T-cell recep-
tor; and (ii) the interaction of B7-1 (CD80) or B7-2 (CD86) with the
co-stimulatory receptor CD28 [36]. After capture of antigen, DCs
lost their ability to acquire antigen but demonstrated an increased
ability to present antigen and enhanced expression of B7 and MHC
molecules [37]. Thus, the expression of B7 and MHC molecules
tends to be a marker for DC maturation and the ability to activate
T cells. Many researches have demonstrated that unmodiﬁed lipo-
some facilitated antigen delivery to DC. In this study, we observed
that BMDCs treated with galactosylated liposomes had higher
expression of CD80, CD86 and MHC II molecules compared with
bare-liposome (Fig. 2B–D). These results indicate both the effective
antigen delivery by targeted galactosylated liposomes and the lipo-
some-enhanced maturation of DCs. The cytokines secreted by DCs
also affect thematuration and development of DCs, thus inﬂuencing
the subsequent immune regulations [38]. The distinct cytokines
secreted by mature DCs ultimately determine their Th1/Th2 polar-
izing capacities. IL-1 and IL-6 are considered the major pro-inﬂam-
matory cytokines that play important roles in the protection
against pathogens during an infection [39]. It has been reported
that IL-12 induces IFN-c secretion from natural killer (NK) cells
and T cells activates NK and T cells, enhances the cytotoxic activity
of NK cells and favors cytotoxic T lymphocyte generation [40]. Thus,
we evaluated cytokine secretion by DCs. The results showed that
stimulating BMDCs with galactosylated liposomes signiﬁcantly
increased IL-1b, IL-6 and IL-12 secretion into the supernatant
(Fig. 3). These results suggest that galactosylated liposomes are
capable of inducing more efﬁcient immune responses than conven-
tional liposomes. According to these in vitro results, we believe that
Fig. 6. Cytokine production from spleen cells after in vitro stimulation. Spleen cells from mice receiving different liposome formulations were obtained 1 week after the ﬁnal
immunization and cultured with 100 lg ml1 OVA for 72 h. The supernatants were collected and the production of cytokines IFN-c, IL-4, IL-5 and IL-6 was measured. The
results are expressed as the means ± SE. ⁄Signiﬁcant difference (p < 0.05) compared with the control group; #signiﬁcant difference (p < 0.05) compared with the bare-
liposome group.
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geted mucosal vaccine.
Cancer immunotherapy is the use of the immune system to
reject cancer. There is a large volume of published studies describ-
ing the adjuvant effect of liposomes in the induction of s-IgA, which
provides more cross-protection against viral infection than that
afforded by systemic immunity. However, in an effectively thera-
peutic or protective antitumor immune response, both a humoral
immune response and a cell-mediated immune response must be
launched. Thus, many approaches have attempted to modify the
liposomes or co-administer various immunostimulators with the
liposomes for effective cancer immunotherapy [8]. Recently, Ishii
and Kojima [41] demonstrated that intranasal administration of
mannose-modiﬁed liposomes without other adjuvants induced
antigen-speciﬁc serum IgG and IgA as well as IFN-c and IL-5 secre-
tion by spleen cells. In the current study, our results have shown
that nasal administration with OVA-encapsulated alpha- or beta-
galactosylated liposomes induced higher serum IgG titers than
bare-liposomes or gal-mixed-liposomes (Fig. 5). Furthermore, fol-
lowing an immunization boost, we observed a signiﬁcant increase
in serum OVA-speciﬁc antibodies over that of the primary immuni-
zation (data no shown), demonstrating that liposomes are able toinduce an anamnestic immune response. The levels of IFN-c and
IL-4 were quantiﬁed to evaluate the Th1 and Th2 immune
responses. Spleen cells from mice immunized with galactosylated
liposomes produced signiﬁcantly increased amounts of IFN-c after
in vitro stimulation with OVA. These results indicate that intranasal
immunization of galactosylated liposomes can trigger a better Th1
immune response. We further analyzed the IFN-c producing
CD8 + T cells after stimulating spleen cells with OVA. We observed
that the number of IFN-c secreting CD8 + T cells was signiﬁcantly
increased in galactosylated liposome-immunized mice compared
with those in the bare-liposome andmixed-liposome groups. Based
on these results, we suggested that efﬁcient antigen delivery of
galactosylated liposomes up-regulates pro-inﬂammatory cytokine
(IL-1b, IL-6 and IL-12) secretion and increases the expression of
co-stimulatory molecules and MHC II molecules on DCs, which
are essential for the induction of a Th1/Th2 immune response in
mice. As a result, galactosylated liposomes effectively enhance the
immune response without an additional immunostimulator.
Many studies have indicated that tumor cell lysates could be
used to induce a sufﬁcient anti-tumor immune response. There-
fore, particle-based antigen delivery systems were developed in
tumor-associated antigen (TAA)-based cancer immunotherapy for
Fig. 7. IFN-c producing CD8 + T cell analysis. Spleen cells (5  106 cells ml1) from mice receiving different liposome formulations were incubated with 100 lg ml–1 OVA for
72 h and 1 ll ml–1 GolgiPlug was added during the last 5 h. Intracellular staining was performed with BD Cytoﬁx/Cytoperm. (A) IFN-c producing CD8 + T cells were analyzed
by FACS. Similar results were obtained in four separate experiments. (B) The percentage of IFN-c producing CD8 + T cells was scored and represented in a histogram with the
bar as the mean ± SE of four independent experiments. ⁄Signiﬁcant difference (p < 0.05) compared with the control group; #signiﬁcant difference (p < 0.05) compared with
the bare-liposome group.
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Fig. 8. Growth of E.G7-OVA tumors in mice immunized intranasally with galactosylated liposomes. C57BL/6 mice were immunized with bare-liposomes, gal-mixed-
liposomes, alpha-gal-liposomes, beta-gal-liposomes or PBS (control). (A) Individual tumor growth curves from mice injected s/c/with 2  105 E.G7-OVA cells 1 week after the
ﬁnal immunization. Boxed fractions indicate complete rejections after tumor inoculation. (B) The average tumor volume in each group. The results are expressed as
means ± SE. ⁄Signiﬁcant difference (p < 0.05) compared with the control group.
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E.G7-OVA cell line, an EL4 cell line that stably transfected with
cDNA of OVA to allow constitutive production of OVA with an
H-2Kb-restricted CTL epitope [42], is a suitable model system for
studying MHC class I restricted responses of cytotoxic T lympho-
cytes in mice. In this study, we used an s.c. E.G7-OVA tumor
protection model to evaluate galactosylated liposomes inducing
an in vivo antitumor effect. In Fig. 8, 5/6 and 6/6 mice receiving
alpha-gal-liposomes and beta-gal-liposomes, respectively, com-
pletely rejected the tumor challenge. By contrast, only 2 and 1 mice
receiving bare-liposomes and gal-mixed-liposomes, respectively,
completely rejected the tumor challenge after tumor inoculation.
These results indicate that intranasally immunized galactosylated
liposomes might be more effectively taken up by DCs in the NALT,
subsequently triggering DCs to mature and migrate to the systemic
circulation, thus resulting in the induction of local and systemic
immune responses. Thus, vaccination with galactosylated lipo-
somes, especially beta-gal-liposomes, was able to achieve more
effective protective anti-tumor effects.5. Conclusion
In this study, we report that galactosylated liposomes effec-
tively facilitated antigen uptake by DCs in vitro and in vivo, leading
to an increase of cytokine production. Moreover, mice receiving
intranasally administrated galactosylated liposomes showed sig-
niﬁcant increases in serum IgG antibody levels and activity of
spleen cells, which led to an efﬁcient anti-OVA immune response
against EG7 tumor challenge. Our results suggest that galactosylat-
ed liposomes could elicit not only antibody immune responses but
also systemic anti-tumor immunity. Recently, many studies have
focused on designing cancer vaccines for the treatment of mucosal
tumors. Sandoval et al. have reported that the growth of orthotopic
head and neck or lung cancers was inhibited when a cancer vaccine
was delivered via the intranasal mucosal route but not by the
intramuscular route [43]. Thus, we suggest that intranasal vaccina-
tion with galactosylated liposomes, especially beta-gal-liposomes,
was able to achieve more effective protective effects that will be
useful for the treatment of mucosal tumors.
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